MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression - Aix-Marseille Université Access content directly
Journal Articles Biomarker Research Year : 2022

MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression

Giuseppina Catanzaro
  • Function : Author
Zein Mersini Besharat
  • Function : Author
Andrea Carai
  • Function : Author
Natalie Jäger
  • Function : Author
Elena Splendiani
  • Function : Author
Agnese Po
  • Function : Author
Martina Chiacchiarini
  • Function : Author
Anna Citarella
  • Function : Author
Francesca Gianno
  • Function : Author
Antonella Cacchione
  • Function : Author
Evelina Miele
  • Function : Author
Francesca Diomedi Camassei
  • Function : Author
Marco Gessi
  • Function : Author
Luca Massimi
  • Function : Author
Franco Locatelli
  • Function : Author
David Jones
  • Function : Author
Stefan Pfister
  • Function : Author
Angela Mastronuzzi
  • Function : Author
Felice Giangaspero
  • Function : Author
Elisabetta Ferretti
  • Function : Author

Abstract

Background Pediatric low-grade gliomas (pLGGs), particularly incompletely resected supratentorial tumours, can undergo progression after surgery. However to date, there are no predictive biomarkers for progression. Here, we aimed to identify pLGG-specific microRNA signatures and evaluate their value as a prognostic tool. Methods We identified and validated supratentorial incompletey resected pLGG-specific microRNAs in independent cohorts from four European Pediatric Neuro-Oncology Centres. Results These microRNAs demonstrated high accuracy in differentiating patients with or without progression. Specifically, incompletely resected supratentorial pLGGs with disease progression showed significantly higher miR-1248 combined with lower miR-376a-3p and miR-888-5p levels than tumours without progression. A significant ( p < 0.001) prognostic performance for miR-1248 was reported with an area under the curve (AUC) of 1.00. We also highlighted a critical oncogenic role for miR-1248 in gliomas tumours. Indeed, high miR-1248 levels maintain low its validated target genes (CDKN1A (p21)/FRK/SPOP/VHL/MTAP) and consequently sustain the activation of oncogenic pathways. Conclusions Altogether, we provide a novel molecular biomarker able to successfully identify pLGG patients associated with disease progression that could support the clinicians in the decision-making strategy, advancing personalized medicine.
Fichier principal
Vignette du fichier
s40364-022-00389-x.pdf (1.8 Mo) Télécharger le fichier
Origin Publisher files allowed on an open archive
Licence

Dates and versions

hal-03982375 , version 1 (18-10-2023)

Licence

Identifiers

Cite

Giuseppina Catanzaro, Zein Mersini Besharat, Andrea Carai, Natalie Jäger, Elena Splendiani, et al.. MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression. Biomarker Research, 2022, 10 (1), pp.44. ⟨10.1186/s40364-022-00389-x⟩. ⟨hal-03982375⟩
24 View
3 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More